Drug Development

You have been asked to write a short report for the board of a healthcare provider who have to make a funding decision: only one of two treatments can be underwritten. The first treatment is Travuda® which is indicated as a prophylactic medicine to prevent HIV infection after unprotected sex. The second treatment is Harvoni®, a combination of ledipasvir and sofosbuvir, which is used to treat Hepatitis C. Set out the arguments for and against funding each treatment and make a recommendation as to which one to fund